CA2932553A1 - Prostate cancer classification - Google Patents

Prostate cancer classification Download PDF

Info

Publication number
CA2932553A1
CA2932553A1 CA2932553A CA2932553A CA2932553A1 CA 2932553 A1 CA2932553 A1 CA 2932553A1 CA 2932553 A CA2932553 A CA 2932553A CA 2932553 A CA2932553 A CA 2932553A CA 2932553 A1 CA2932553 A1 CA 2932553A1
Authority
CA
Canada
Prior art keywords
prostate cancer
subject
expression level
sample
srsf5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2932553A
Other languages
English (en)
French (fr)
Inventor
Steven Walker
Andrena MCCAVIGAN
Timothy Davison
Richard Kennedy
Paul Harkin
Laura Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of CA2932553A1 publication Critical patent/CA2932553A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2932553A 2013-12-12 2014-12-12 Prostate cancer classification Abandoned CA2932553A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322034.8A GB201322034D0 (en) 2013-12-12 2013-12-12 Prostate cancer classification
GB1322034.8 2013-12-12
PCT/GB2014/053694 WO2015087088A2 (en) 2013-12-12 2014-12-12 Prostate cancer classification

Publications (1)

Publication Number Publication Date
CA2932553A1 true CA2932553A1 (en) 2015-06-18

Family

ID=50030858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932553A Abandoned CA2932553A1 (en) 2013-12-12 2014-12-12 Prostate cancer classification

Country Status (13)

Country Link
US (1) US10196697B2 (enExample)
EP (1) EP3080293B1 (enExample)
JP (1) JP2017507320A (enExample)
KR (1) KR20160098351A (enExample)
CN (1) CN105940117A (enExample)
AU (1) AU2014363173A1 (enExample)
BR (1) BR112016013182A2 (enExample)
CA (1) CA2932553A1 (enExample)
GB (1) GB201322034D0 (enExample)
IL (1) IL246067A0 (enExample)
MX (1) MX2016007333A (enExample)
SG (1) SG11201604508PA (enExample)
WO (1) WO2015087088A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881627C (en) 2012-08-16 2024-09-10 Mayo Foundation For Medical Education And Research CANCER DIAGNOSIS USING BIOMARKERS
CA2996426A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US20190024184A1 (en) * 2015-12-23 2019-01-24 Fred Hutchinson Cancer Research Center Distinguishing metastatic-lethal prostate cancer from indolent prostate cancer using methylation status of epigenetic markers
AU2017209307B2 (en) 2016-01-20 2023-06-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CA3055925A1 (en) * 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
WO2019195658A1 (en) * 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
CN109295208A (zh) * 2018-10-26 2019-02-01 德阳市人民医院 Pi15作为骨关节炎标志物的应用
PH12021551788A1 (en) * 2019-01-30 2022-05-23 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
GB201917428D0 (en) * 2019-11-29 2020-01-15 Univ Newcastle Prostate cancer diagnostic
CN111518908B (zh) * 2020-05-18 2023-10-17 奥尔文泰生物科技(杭州)有限公司 尿液前列腺癌标志物组合及其在制备精准诊断试剂中的用途
EP3960877A1 (en) * 2020-08-31 2022-03-02 Koninklijke Philips N.V. Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject
EP3960878A1 (en) * 2020-08-31 2022-03-02 Koninklijke Philips N.V. Selection of a dose for radiotherapy of a prostate cancer subject
EP3960876A1 (en) * 2020-08-31 2022-03-02 Koninklijke Philips N.V. Prediction of a response of a prostate cancer subject to radiotherapy based on pde4d7 correlated genes
JP7477872B2 (ja) * 2020-09-30 2024-05-07 国立大学法人大阪大学 癌に関連する新規バイオマーカー
CN113234820A (zh) * 2021-04-29 2021-08-10 北京艾克伦医疗科技有限公司 鉴定前列腺癌状态的方法和试剂盒
WO2023135485A1 (en) * 2022-01-13 2023-07-20 Oslo Universitetssykehus Hf Prostate cancer markers and uses thereof
EP4253567A1 (en) * 2022-03-31 2023-10-04 OncoAssure Limited A method of predicting risk of an aggressive or recurrent cancer
WO2023220314A1 (en) * 2022-05-12 2023-11-16 Veracyte SD, Inc. Prognosis and treatment of molecular subtypes of prostate cancer
CN116891523B (zh) * 2023-05-24 2024-05-17 深圳晶蛋生物医药科技有限公司 一种trpm3截短体、包含其的细胞系及其用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774121B2 (ja) 1987-07-31 1998-07-09 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 標的ポリヌクレオチド配列の選択的増幅
KR0148265B1 (ko) 1988-12-16 1998-10-15 에프.지이.엠 헤르만스 자가-지속 서열 복제 시스템
US5437975A (en) 1991-02-25 1995-08-01 California Institute Of Biological Research Consensus sequence primed polymerase chain reaction method for fingerprinting genomes
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US7220557B2 (en) 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20050032065A1 (en) 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
WO2005083118A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Pin-prc transition genes
WO2006091776A2 (en) 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US8349555B2 (en) 2005-03-16 2013-01-08 Gennadi V. Glinsky Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
EP1717320A1 (en) 2005-04-26 2006-11-02 TopoTarget Germany AG Identification of human gene sequences of cancer antigens expressed in metastatic carcinoma and involved in metastasis formation, and their use in cancer diagnosis, prognosis and therapy
DE602006018038D1 (de) 2005-09-14 2010-12-16 Nat Res Council Canada Ottawa Molekulares verfahren zur diagnose von prostatakrebs
US20070059753A1 (en) 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
CA2629008A1 (en) 2005-11-08 2007-09-13 Euclid Diagnostics Llc Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110045464A1 (en) 2007-01-10 2011-02-24 Henry Ford Health System Methods and compositions for identification of prostate cancer markers
US20100233691A1 (en) 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
JP2010536844A (ja) 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 癌の治療標的及び診断マーカーとしてのｄｋｋ１癌遺伝子
WO2009151503A2 (en) 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
JP2011516077A (ja) 2008-04-11 2011-05-26 チャイナ シンセティック ラバー コーポレイション 癌を検出するための方法、薬剤、およびキット
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
US20090298082A1 (en) 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
EP2405022A3 (en) 2008-07-08 2012-05-02 Genomic Health, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
MX2011000451A (es) 2008-07-16 2011-10-12 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con cancer de próstata y métodos para utilizarlos.
US20100055705A1 (en) 2008-08-29 2010-03-04 Wilson Gerald M Compositions and methods for diagnosing and treating cancer
CN102308004A (zh) 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP2430190B1 (en) 2009-05-12 2018-11-21 Koninklijke Philips N.V. Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
ES2700877T3 (es) 2009-05-12 2019-02-19 Koninklijke Philips Nv Fosfodiesterasa 4D7 como marcador de cáncer de próstata
EP2804001B1 (en) 2009-06-04 2017-08-09 Metanomics Health GmbH Methods for diagnosing prostate carcinomas
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
EP2309273B1 (en) 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
AU2010326066A1 (en) 2009-12-01 2012-06-21 Compendia Bioscience, Inc. Classification of cancers
WO2011094233A1 (en) * 2010-01-26 2011-08-04 The Johns Hopkins University Methods of disease classification or prognosis for prostate cancer based on expression of cancer/testis antigens
US20130058925A1 (en) * 2010-02-26 2013-03-07 Board Of Regents, The University Of Texas System Epithelial biomarkers for cancer prognosis
SG10201501857YA (en) * 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
CA2836725A1 (en) * 2010-06-01 2011-12-08 Indiana University Research And Technology Corporation Materials and methods for diagnosing and predicting the course of prostate cancer
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP2598890A4 (en) * 2010-07-26 2013-12-25 Univ Johns Hopkins MIG6 AND THERAPEUTIC EFFECTIVENESS THEREOF
JP2013532482A (ja) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いた前立腺癌の予後を定量化する方法
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
BR112013027583A2 (pt) 2011-04-28 2016-09-06 Alexander Pearlman assinaturas genômicas de metástases em câncer de próstata
AU2012275500A1 (en) * 2011-06-27 2014-01-16 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with prostate cancer progression and methods of use thereof
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
GB201206209D0 (en) 2012-04-06 2012-05-23 Univ Leuven Kath Marker gene based diagnosis, staging and prognosis of prostate caner
DK2794880T3 (en) 2011-12-22 2018-07-23 Ionis Pharmaceuticals Inc METHOD OF MODULATING METASTASE-ASSOCIATED-IN-LONG-ADENOCARCINOM TRANSCRIPT-1- (MALATE-1) EXPRESSION
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
TW201343920A (zh) 2012-03-29 2013-11-01 財團法人國家衛生研究院 預測前列腺癌預後之分子標記、方法與套組
BR102012007246A2 (pt) * 2012-03-30 2016-02-10 Fundação Antonio Prudente métodos para prognóstico e classificação de resultados de um evento
US20130288967A1 (en) 2012-04-25 2013-10-31 Euclid Diagnostics Llc Materials and methods for cancer diagnosis by evaluation of the methylation status of cpg islands on chromosomes 6 and 8
CN103146688B (zh) 2012-09-12 2015-05-13 上海长海医院 长链非编码rna作为疾病诊断血液分子标志物的应用

Also Published As

Publication number Publication date
BR112016013182A2 (pt) 2017-09-26
MX2016007333A (es) 2016-10-13
US10196697B2 (en) 2019-02-05
JP2017507320A (ja) 2017-03-16
GB201322034D0 (en) 2014-01-29
EP3080293A2 (en) 2016-10-19
WO2015087088A3 (en) 2015-09-17
AU2014363173A1 (en) 2016-07-07
KR20160098351A (ko) 2016-08-18
SG11201604508PA (en) 2016-07-28
EP3080293B1 (en) 2019-03-13
CN105940117A (zh) 2016-09-14
US20160312294A1 (en) 2016-10-27
WO2015087088A2 (en) 2015-06-18
IL246067A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
EP3080293B1 (en) Prostate cancer classification
Bibikova et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer
Valdes-Mora et al. Prostate cancer epigenetic biomarkers: next-generation technologies
Linton et al. Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours
AU2019250606B2 (en) Improved classification and prognosis of prostate cancer
EP3310927B1 (en) Gene signatures predictive of metastatic disease
WO2008104543A2 (en) Method for predicting the occurrence of metastasis in breast cancer patients
Kanda et al. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer
CA2961725C (en) A method of predicting risk of recurrence of cancer
WO2015073949A1 (en) Method of subtyping high-grade bladder cancer and uses thereof
WO2012125411A1 (en) Methods of predicting prognosis in cancer
Strand et al. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy
US20160355889A1 (en) Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
Farkas et al. Epigenetic changes as prognostic predictors in endometrial carcinomas
Amato et al. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes
Kim et al. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer
Huang et al. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival
WO2015127101A1 (en) Method and composition for diagnosis of aggressive prostate cancer
Goh et al. Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer
US20230416841A1 (en) Inferring transcription factor activity from dna methylation and its application as a biomarker
Moğul et al. The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma
Snyder et al. Discovery and Validation of Clinically Relevant Long Non-Coding RNAs in Colorectal Cancer. Cancers 2022, 14, 3866
Mazumder et al. Molecular and cellular approaches to patient management in oncology
Baehner and Predictive Assays
Barış Moğul et al. The Pd-L1 Promoter Methylation Predicts Gene and Protein Expression Levels in Urothelial Carcinoma

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181212

FZDE Discontinued

Effective date: 20181212